Fig. 4 | Hypertension Research

Fig. 4

From: Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

Fig. 4

Geometric mean percent changes in the urine albumin-to-creatine ratio (UACR) from the baseline to the end of treatment in all patients (a) and stratified by the end-of-treatment dosage of esaxerenone (b). Data are geometric mean and 95% confidence interval. *p < 0.05, paired t-test for changes from the baseline (b post hoc analysis). Full analysis set, n = 47

Back to article page